Logo image of 2X1.DE

ABIVAX SA (2X1.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:2X1 - FR0012333284 - Common Stock

120.6 EUR
-2 (-1.63%)
Last: 12/30/2025, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 2X1. 2X1 was compared to 81 industry peers in the Biotechnology industry. 2X1 may be in some trouble as it scores bad on both profitability and health. 2X1 is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year 2X1 has reported negative net income.
In the past 5 years 2X1 always reported negative net income.
In the past 5 years 2X1 always reported negative operating cash flow.
2X1.DE Yearly Net Income VS EBIT VS OCF VS FCF2X1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of 2X1 (-105.39%) is worse than 76.54% of its industry peers.
Industry RankSector Rank
ROA -105.39%
ROE N/A
ROIC N/A
ROA(3y)-74.5%
ROA(5y)-62.73%
ROE(3y)-491.9%
ROE(5y)-484.88%
ROIC(3y)N/A
ROIC(5y)N/A
2X1.DE Yearly ROA, ROE, ROIC2X1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

2X1 does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2X1.DE Yearly Profit, Operating, Gross Margins2X1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, 2X1 has about the same amount of shares outstanding.
2X1 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 2X1 has a worse debt to assets ratio.
2X1.DE Yearly Shares Outstanding2X1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
2X1.DE Yearly Total Debt VS Total Assets2X1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 25.06 indicates that 2X1 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 25.06, 2X1 belongs to the top of the industry, outperforming 95.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 25.06
ROIC/WACCN/A
WACCN/A
2X1.DE Yearly LT Debt VS Equity VS FCF2X1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

2X1 has a Current Ratio of 1.25. This is a normal value and indicates that 2X1 is financially healthy and should not expect problems in meeting its short term obligations.
2X1 has a worse Current ratio (1.25) than 66.67% of its industry peers.
A Quick Ratio of 1.25 indicates that 2X1 should not have too much problems paying its short term obligations.
2X1's Quick ratio of 1.25 is on the low side compared to the rest of the industry. 2X1 is outperformed by 61.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.25
2X1.DE Yearly Current Assets VS Current Liabilites2X1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.37% over the past year.
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -2.16% on average over the next years.
Based on estimates for the next years, 2X1 will show a very strong growth in Revenue. The Revenue will grow by 179.09% on average per year.
EPS Next Y-3.44%
EPS Next 2Y32.6%
EPS Next 3Y-2.16%
EPS Next 5YN/A
Revenue Next Year91.53%
Revenue Next 2Y16.32%
Revenue Next 3Y246.09%
Revenue Next 5Y179.09%

3.3 Evolution

2X1.DE Yearly Revenue VS Estimates2X1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
2X1.DE Yearly EPS VS Estimates2X1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

2X1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 2X1. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2X1.DE Price Earnings VS Forward Price Earnings2X1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
2X1.DE Per share data2X1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

2X1's earnings are expected to decrease with -2.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.6%
EPS Next 3Y-2.16%

More info and screens

0

5. Dividend

5.1 Amount

2X1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ABIVAX SA

FRA:2X1 (12/30/2025, 7:00:00 PM)

120.6

-2 (-1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-15 2025-12-15
Earnings (Next)03-23 2026-03-23/amc
Inst Owners41.18%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.39B
Revenue(TTM)N/A
Net Income(TTM)-176.00M
Analysts85.71
Price Target114.13 (-5.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.33%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)-8.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.8
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.09
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -105.39%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.5%
ROA(5y)-62.73%
ROE(3y)-491.9%
ROE(5y)-484.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.25
Altman-Z 25.06
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.27%
Cap/Depr(5y)310.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.06%
EPS Next Y-3.44%
EPS Next 2Y32.6%
EPS Next 3Y-2.16%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year91.53%
Revenue Next 2Y16.32%
Revenue Next 3Y246.09%
Revenue Next 5Y179.09%
EBIT growth 1Y-36.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.57%
EBIT Next 3Y14.09%
EBIT Next 5YN/A
FCF growth 1Y-58.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.76%
OCF growth 3YN/A
OCF growth 5YN/A

ABIVAX SA / 2X1.DE FAQ

What is the ChartMill fundamental rating of ABIVAX SA (2X1.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to 2X1.DE.


What is the valuation status of ABIVAX SA (2X1.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIVAX SA (2X1.DE). This can be considered as Overvalued.


What is the profitability of 2X1 stock?

ABIVAX SA (2X1.DE) has a profitability rating of 0 / 10.